ASH 2024 | A Phase Ib trial investigating the combination of ruxolitinib and duvelisib in R/R T-cell lymphoma

So we presented the results of the study, which was a Phase Ib study evaluating ruxolitinib plus duvelisib in relapsed/refractory T-cell lymphoma. The study started off with a dose-finding part, and we found that the maximum tolerated dose was ruxolitinib 20 milligrams BID plus duvelisib 25 milligrams BID. And then we expanded to evaluate the efficacy. Altogether, there were about 49 patients on the study. And the thing that we found that was most intriguing was that there were two groups that seemed to benefit the most from this combination. The first group were the patients with T follicular helper lymphomas. Those patients had a particularly high overall response rate as well as complete response rate. There were 14 of those patients on the study. So it’s still a small group, but really nice activity amongst that group. And then the other group, a pretty rare subtype of T-cell lymphoma, T-PLL, or T-prolymphocytic leukemia, that’s rare and can be difficult to treat and tends to be, there’s not many treatment options. And so we had five patients with that entity on the study as well, and the overall response rate amongst those patients was 60%, but actually four out of five of those patients had significant clinical benefit. So at this point it’s small numbers amongst those groups but really nice signals and so we are expanding that study to look more within both T follicular helper as well as T-PLL and so that will allow us to further evaluate the efficacy in both those groups and confirm if the signal that we’re seeing is truly real.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.